Liverpool Uni leads EU kidney research project
Liverpool University is to coordinate a European research project that aims to develop new devices and methods for diagnosing and treating kidney disease.
9th November 2018
Latest news
Hikma, Vectura to develop generic rivals to GSK's Ellipta portfolio
Hikma Pharmaceuticals and Vectura have signed a deal to develop and market generic versions of GlaxoSmithKline's Ellipta portfolio, utilising the latter’s Open-Inhale-Close dry powder inhaler device.
9th November 2018
Mallinckrodt’s Niemann-Pick Type C drug fails to hit trial target
UK-based Mallinckrodt has revealed that its experimental therapy for Niemann-Pick Type C failed to hit targets in a recently completed registration trial.
8th November 2018
NICE nod for Jazz’ AML chemo
Jazz Pharmaceuticals’ chemotherapy Vyxeos has won the backing of the National Institute for Health and Care Excellence (NICE) for routine use on the NHS in England and Wales to treat certain acute myeloid leukaemias (AML).
8th November 2018
AZ books sales growth for the third quarter
AstraZeneca’s product sales returned to growth in the third quarter, with new medicines and emerging markets driving performance.
8th November 2018
New alliance strives to advance human-based drug evaluation
Medicines Discovery Catapult and the Medical Research Council (MRC) Centre for Drug Safety Science (CDSS) at the University of Liverpool have announced plans to work together on the development of next generation human cell models to advance human based drug discovery.
8th November 2018
Entries now underway - showcase your talent alongside the best in the industry
The PharmaTimes International Clinical Researcher of the Year 2019 has been designed to recognise and reward the talent of entrants from all parts of the globe in this ultimate test.
8th November 2018
AZ sells respiratory trio to Covis
AstraZeneca has handed over rights to a trio of non-core assets to Covis Pharma, as it continues to shed parts of its portfolio.
6th November 2018
Priority review for Sanofi, Regeneron’s Dupixent
Sanofi and Regeneron’s biologic Dupixent has been granted a priority review in the US for use to treat certain adolescent patients with moderate-to-severe atopic dermatitis.
6th November 2018
Social media scheme boosts breast cancer screening uptake
An NHS project using social media has driven a 13% increase in first time attendances for breast screening in Stoke-on-Trent over four years.
6th November 2018
Health secretary throws his weight behind social prescribing
Health secretary Matt Hancock has announced plans to establish a National Academy for Social Prescribing to lead the practice under a renewed drive to improve the prevention of ill health.
6th November 2018
US approves new use for BMS’ Empliciti
US regulators have expanded the treatment scope of Bristol-Myers Squibb’s Empliciti allowing its use plus pomalidomide and dexamethasone (EPd) for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.
6th November 2018
Five new technology centres to drive earlier diagnoses
Business Secretary Greg Clark has announced five new centres of excellence for digital pathology and imaging in England, which will use advances in medical artificial intelligence to diagnose diseases at an earlier stage.
6th November 2018
Health secretary unveils plans for greater focus on ill health prevention
Health secretary Matt Hancock is planning to breathe new life into the government’s approach to prevention of ill health, with a shift in focus to primary and community services.
6th November 2018
Lilly says Trulicity cut risk of CV events in wide patient group
Lilly says its once-weekly diabetes drug Trulicity cut major adverse cardiovascular events (MACE) in patients taking part in the REWIND trial.
6th November 2018
